Plant Patent Infringement in the US Relies on Evidence of Asexual Reproduction

Published April 2025

Plant Patent Infringement in the US Relies on Evidence of Asexual Reproduction

A recent case in the US District Court for the Northern District of Texas (Dallas Division) once again highlights how important the initial pleadings and evidence in patent infringement cases can be.

The case is between David Austin Roses Ltd and GCM Ranch LLC[1] and is based on alleged willful infringement of US plant patents held by David Austin covering several varieties of roses, and corresponding trademark infringement. David Austin Roses Ltd is a major British rose breeding company. The varieties bred by David Austin are well known as the company has been established for a long time and consistently obtains PVR protection for its roses around the world, including under the US Plant Patent Act. They also typically file trademarks for the tradenames of each rose covered under a corresponding plant patent.

In this case, David Austin alleged that GCM Ranch infringed nine granted US plant patents by selling rose varieties that fall under the plant patent claims. However the evidence they provided in their pleadings was based mostly on screenshots of the rose products on the GCM Ranch websites resembling the patented varieties, and reviews indicating sale of the products to consumers.

In response, GCM Ranch argued that the evidence was not sufficient to prove patent infringement because David Austin failed to provide any explanation of how the alleged infringing plants were produced. According to USC 163, in the case of a plant patent, the grant shall ‘include the right to exclude others from asexually reproducing the plant, and from using, offering for sale, or selling the plant so reproduced, or any of its parts, throughout the United States’.  It was clear that David Austin demonstrated that the plant was being offered for sale and sold, but did not satisfy that said plants were proven to be asexually reproduced from the patented plant. GCM Ranch seized on this point of law in their response, as did the Court. Despite the striking similarities in the plants being sold to the protected varieties, and the agreement that GCM Ranch new of the plant patents at issue, the Court granted GCM Ranch’s motion to dismiss the plant patent infringement case. The Court stated that ‘even though the roses resemble one another, David Austin has failed to plausibly allege that GCM Ranch’s roses were asexually reproduced from David Austin’s roses. For example, David Austin did not allege how GCM Ranch was asexually reproducing the patented roses—i.e., whether they did so by grafting, budding, or layering’.

It is clear that for plant patent infringement in the US the pleadings must be sure to provide factual evidence of how the infringing plants were actually derived from the patented plant, in addition to evidence of sales of the infringing plants. It seems that simply alleging that the patented plant variety has been asexually reproduced is not enough. A full case should be presented at the pleadings stage to avoid surprising dismissal.

[1] https://archive.org/details/gov.uscourts.txnd.388559/gov.uscourts.txnd.388559.33.0.pdf


This post was written by Partner and Patent Attorney Punita Shah and Partner and Patent Attorney Ellie Purnell.

Latest updates

Event - 12th November 2026

HGF Partners with PPTI for 'Designing Foods for Healthy Aging' Webinar

As healthy aging, metabolic health and weight management rise up the consumer agenda, food and nutrition businesses are increasingly looking beyond traditional product development and towards solutions that deliver measurable …

Event details
Event - 14th October 2026

Seminar on the new EU Pharma Package and its implications for regulatory exclusivities in the EU.

We are pleased to invite you to our seminar on the new EU Pharma Package and its implications for regulatory exclusivities in the EU. Speaker: Dr Andrew Wells (Partner and …

Event details
Event - 28th October 2026

HGF Attending BMCS Antibody–Drug Conjugates 2026

HGF is pleased to announce that Dr Thomas Lonsdale, Patent Director, will be attending the BMCS Antibody–Drug Conjugates 2026 meeting, taking place on 19 November 2026 at GSK, Stevenage, UK. …

Event details

Hsu Min Chung Recognised in IAM Global Leaders 2027

HGF is delighted to announce that Partner, Hsu Min Chung, has been recognised in the IAM Global Leaders 2027 guide, a prestigious ranking that highlights some of the world’s leading …

Read article
Event - 28th October 2026

HGF Attending the KINPA Conference 2026

HGF is pleased to be attending the KINPA Conference 2026, taking place on 28 October in Seoul, South Korea. Recognised as Korea’s largest intellectual property gathering, the conference brings together …

Event details
Event - 17th - 19th November 2026

HGF Attending IPBC Asia 2026

HGF is pleased to announce that Partner, Dr Jennifer Uno, will be attending IPBC Asia 2026, taking place from 17-19 November 2026 in Tokyo, Japan. The event is one of …

Event details

HGF Recognised in the Chambers and Partners UK 2027 Guide

HGF is proud to announce that we have once again been recognised in the Chambers and Partners UK 2027 Guide, with outstanding rankings for both the firm and individual practitioners …

Read article
Event - 4th November 2026

IAM Navigating the UPC conference

HGF are gold sponsors of the IAM Live Navigating the UPC conference. IAM Live: Navigating the UPC returns to Paris in November bringing together over 180 industry leaders for an …

Event details